Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells
AssigneeBlanchette Rockefeller Neurosciences Institute
InventorsTapan Kumar Khan, Daniel L. Alkon
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for the diagnosis of AD from non-AD conditions by using a PKC Isozyme Index obtained by determining ratios of ratios of different PKC Isozymes in peripheral cells of a test subject in the absence and presence of a beta-amyloid peptide, and optionally, in the presence of a PKC activator.
Claims26
A method for determining the presence or absence of Alzheimer's Disease in a candidate subject, which method comprises:
- i) determining the protein levels of a first PKC isozyme in peripheral cells from a candidate subject in the absence of and in the presence of an Aβ peptide to generate a first ratio;
- ii) determining the protein levels of a second PKC isozyme in peripheral cells from a candidate subject in the absence of and in the presence of the Aβ peptide, wherein the second PKC isozyme is not known to be differentially modulated by the Aβ peptide in AD cells compared to non-AD cells, to generate a second ratio;
- iii) generating a PKC isozyme Index by dividing the first ratio by the second ratio, wherein a PKC isozyme Index of about 1.0 or lower indicates a diagnosis of Alzheimer's Disease and a PKC isozyme Index of greater than 1.0 indicates the absence of Alzheimer's Disease.
A kit comprising one or more Aβ peptides, at least one antibody specific for a PKC isozyme known to be differentially modulated by the Aβ peptide in AD cells compared to non-AD cells;
- at least one antibody specific for a PKC isozyme that is not known to be differentially modulated by the Aβ peptide in AD cells compared to non-AD cells;
- and instructions for determining a PKC Isozyme Index.
Dependencies are inferred from the claim text.